Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5661136 | GENZYME | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents |
Jan, 2018
(6 years ago) | |
US5661136 (Pediatric) | GENZYME | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents |
Jul, 2018
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Dec 28, 2011 |
Pediatric Exclusivity(PED) | Jun 28, 2012 |
Market Authorisation Date: 28 December, 2004
Treatment: Clolar is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens
Dosage: SOLUTION;INTRAVENOUS